Question	Reference Answer	Actual Answer	Correct?	Score	Reasoning
What are the most commonly mutated genes in breast cancer?	TP53, PIK3CA, GATA3, CDH1, ESR1	"The most commonly mutated genes in breast cancer include TP53, PIK3CA, and BRCA1/BRCA2.

Citations:
"	N	0	"The criterion is to assess whether the submission conveys the same primary information as the reference without introducing any contradictions.

The reference lists the most commonly mutated genes in breast cancer as TP53, PIK3CA, GATA3, CDH1, ESR1.

The submission states that the most commonly mutated genes in breast cancer are TP53, PIK3CA, and BRCA1/BRCA2.

Comparing the two, TP53 and PIK3CA are mentioned in both the reference and the submission, indicating that the submission is partially correct. However, the submission includes BRCA1/BRCA2, which are not mentioned in the reference. This introduces a contradiction.

Additionally, the submission does not mention GATA3, CDH1, or ESR1, which are listed in the reference. This means that the submission does not fully convey the primary information from the reference.

Therefore, the submission does not meet the criterion.

N"
Are silent clonal hematopoietic genotypes relevant for patients with nonhematologic cancers?	According to the Cancer Therapy and Clonal Hematopoiesis study, silent clonal hematopoietic genotypes can reveal underlying risks for hematologic malignancies and may influence the management and monitoring strategies for patients with nonhematologic cancers.	"Yes, silent clonal hematopoietic genotypes are relevant for patients with nonhematologic cancers.

Citations:
"	Y	1	"The criterion is to assess if the submission conveys the same primary information as the reference without introducing any contradictions.

The reference states that silent clonal hematopoietic genotypes can reveal underlying risks for hematologic malignancies and may influence the management and monitoring strategies for patients with nonhematologic cancers.

The submission states that silent clonal hematopoietic genotypes are relevant for patients with nonhematologic cancers. This is in line with the reference which suggests that these genotypes may influence management and monitoring strategies for such patients.

Therefore, the submission does not introduce any contradictions and conveys the same primary information as the reference.

Y"
How does the genomic landscape differ between primary and metastatic tumors according to the MSK MetTropism study?	The study found that metastatic tumors often harbor additional mutations not present in primary tumors, indicating genomic evolution during metastasis. This highlights the importance of sequencing metastatic lesions for comprehensive genomic profiling.	"The MSK MetTropism study indicates that primary and metastatic tumors exhibit distinct genomic landscapes, with metastatic tumors often showing more complex alterations and variations in key oncogenes and tumor suppressor genes compared to their primary counterparts.

Citations:
"	Y	1	"The criterion for this task is the correctness of the information provided in the submission, compared to the reference. 

The reference states that the study found metastatic tumors often have additional mutations not present in primary tumors, indicating genomic evolution during metastasis. It also emphasizes the importance of sequencing metastatic lesions for comprehensive genomic profiling.

The submission states that the MSK MetTropism study indicates that primary and metastatic tumors exhibit distinct genomic landscapes, with metastatic tumors often showing more complex alterations and variations in key oncogenes and tumor suppressor genes compared to their primary counterparts.

Both the submission and the reference agree that metastatic tumors often have more complex alterations and variations compared to primary tumors. The submission does not contradict the reference, but rather expands on it by mentioning the variations in key oncogenes and tumor suppressor genes. 

Therefore, the submission meets the criterion of correctness.

Y"
What are the key genomic differences between lung adenocarcinomas and squamous cell carcinomas identified in the Pan-Lung Cancer TCGA study?	The study identified distinct mutational profiles for each subtype, with adenocarcinomas frequently exhibiting EGFR mutations, while squamous cell carcinomas showed alterations in genes like TP53 and CDKN2A, underscoring the need for subtype-specific therapeutic approaches.	"Key genomic differences identified between lung adenocarcinomas and squamous cell carcinomas in the Pan-Lung Cancer TCGA study include variations in mutation profiles, copy number alterations, and gene expression patterns. Lung adenocarcinomas often show mutations in genes such as EGFR and KRAS, while squamous cell carcinomas frequently exhibit mutations in TP53 and alterations in the CDKN2A locus. Additionally, distinct pathways and biologic processes are associated with each subtype.

Citations:
"	Y	1	"The criterion for this task is correctness, which means the submission should convey the same primary information as the reference without introducing any contradictions.

Looking at the submission, it mentions that the Pan-Lung Cancer TCGA study identified key genomic differences between lung adenocarcinomas and squamous cell carcinomas. These differences include variations in mutation profiles, copy number alterations, and gene expression patterns. The submission also specifies that lung adenocarcinomas often show mutations in genes such as EGFR and KRAS, while squamous cell carcinomas frequently exhibit mutations in TP53 and alterations in the CDKN2A locus. 

Comparing this to the reference, the primary information is consistent. The reference also mentions that the study identified distinct mutational profiles for each subtype, with adenocarcinomas frequently exhibiting EGFR mutations, while squamous cell carcinomas showed alterations in genes like TP53 and CDKN2A. 

The submission does not introduce any contradictions to the reference. However, it does provide additional information not mentioned in the reference, such as the mention of KRAS mutations in adenocarcinomas and the reference to distinct pathways and biologic processes associated with each subtype. This additional information does not contradict the reference, but rather expands on it.

Therefore, based on the criterion of correctness, the submission meets the criteria.

Y"
Which KRAS mutations are most common in colorectal cancer?	G12D, G12V, G12C, G12A, G12S, G13D	"The most common KRAS mutations in colorectal cancer are G12D, G12V, and G13D.

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference. 

The reference lists six KRAS mutations common in colorectal cancer: G12D, G12V, G12C, G12A, G12S, G13D.

The submission mentions three KRAS mutations: G12D, G12V, and G13D.

Comparing the submission with the reference, it is clear that the submission does not include all the mutations listed in the reference. It misses out on G12C, G12A, and G12S.

Therefore, the submission does not meet the criterion of conveying the same primary information as the reference without introducing any contradictions.

N"
What therapeutic strategies are suggested by the dominant molecular alterations and immune landscape features characteristic of upper tract urothelial carcinoma?	The presence of activated FGFR3 signaling and a T-cell depleted microenvironment suggests that FGFR3 inhibitors and strategies to modulate the immune contexture could be effective therapeutic approaches.	"Therapeutic strategies suggested by the dominant molecular alterations and immune landscape features of upper tract urothelial carcinoma include targeting specific genetic mutations, employing immunotherapy to enhance immune response, and utilizing combination therapies that address both tumor biology and the immune microenvironment.

Citations:
"	N	0	"The criterion for this task is correctness, which requires the submission to convey the same primary information as the reference without introducing any contradictions.

Looking at the reference, the primary information is that the presence of activated FGFR3 signaling and a T-cell depleted microenvironment suggests that FGFR3 inhibitors and strategies to modulate the immune contexture could be effective therapeutic approaches for upper tract urothelial carcinoma.

Comparing this with the submission, it is clear that the submission does not mention the specific FGFR3 inhibitors or strategies to modulate the immune contexture. Instead, it talks about targeting specific genetic mutations, employing immunotherapy, and utilizing combination therapies. While these strategies could potentially include FGFR3 inhibitors and immune modulation, the submission does not explicitly state this.

Therefore, the submission does not convey the same primary information as the reference and introduces new information that is not present in the reference. This means it does not meet the criterion of correctness.

N"
What is the average number of driver mutations found per cancer genome in PCAWG study?	The PCAWG study found that, on average, each cancer genome harbored 4 to 5 driver mutations when considering both coding and non-coding genomic elements.	"The average number of driver mutations found per cancer genome in the PCAWG study is approximately 5.6.

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference provided. 

The reference states that the PCAWG study found an average of 4 to 5 driver mutations per cancer genome. 

The submission, however, states that the average number of driver mutations per cancer genome in the PCAWG study is approximately 5.6. 

This introduces a contradiction as the number provided in the submission is higher than the range provided in the reference. 

Therefore, the submission does not meet the criterion. 

N"
Are there molecular subtypes of meningioma that correlate with clinical behavior or prognosis?	es, meningiomas can be classified into molecular subtypes, including NF2-mutated, TRAF7/KLF4-mutated, SMARCB1-mutated, and POLR2A-mutated groups, each associated with distinct clinical behaviors and prognoses.	"Yes, there are molecular subtypes of meningioma that correlate with clinical behavior and prognosis.

Citations:
"	N	0	"The criterion for this task is correctness, which requires the submission to convey the same primary information as the reference without introducing any contradictions. 

Looking at the reference, it states that meningiomas can be classified into molecular subtypes, and it lists specific examples of these subtypes (NF2-mutated, TRAF7/KLF4-mutated, SMARCB1-mutated, and POLR2A-mutated groups). It also mentions that these subtypes are associated with distinct clinical behaviors and prognoses.

The submission, on the other hand, simply states that there are molecular subtypes of meningioma that correlate with clinical behavior and prognosis. While this is not incorrect, it does not convey the same level of detail as the reference. The submission does not mention the specific subtypes or the fact that they are associated with distinct clinical behaviors and prognoses.

Therefore, the submission does not fully meet the criterion of correctness as it does not convey the same primary information as the reference.

N"
What molecular subgroups are identified in early-onset prostate cancer?	Early-onset prostate cancer can be classified into four molecular subgroups: one defined by SPOP and FOXA1 mutations without ETS gene fusions; another characterized by TMPRSS2–ERG fusions with high androgen receptor signaling; a third marked by high ESRP1 expression driven by 8q duplication and associated with aggressive behavior; and a heterogeneous group lacking these defining features. These subtypes reflect distinct biological pathways and clinical profiles.	"The molecular subgroups identified in early-onset prostate cancer include the androgen receptor-driven subtype, the ERG rearrangement subtype, and others that may reflect distinct biological characteristics and clinical behaviors.

Citations:
"	N	0	"The criterion for this task is the correctness of the information provided in the submission, compared to the reference. 

The reference mentions four molecular subgroups of early-onset prostate cancer: one defined by SPOP and FOXA1 mutations without ETS gene fusions; another characterized by TMPRSS2–ERG fusions with high androgen receptor signaling; a third marked by high ESRP1 expression driven by 8q duplication and associated with aggressive behavior; and a heterogeneous group lacking these defining features.

The submission, however, only mentions two subgroups: the androgen receptor-driven subtype and the ERG rearrangement subtype. It also vaguely mentions ""others"" without specifying what these are. 

Therefore, the submission does not fully convey the primary information from the reference and introduces a contradiction by not mentioning all the subgroups. 

N"
What genetic alterations drive CDK6-mediated resistance in metastatic breast cancer patients?	The Metastatic Breast Cancer (MSK, Cancer Discovery 2022) study found that genetic alterations such as FAT1 loss, PTEN loss, and ARID1A loss were found to promote CDK6 upregulation and concomitant INK4 protein induction, leading to CDK4/6i resistance. These alterations were present in 17% of metastatic breast cancer patients analyzed.	"CDK6-mediated resistance in metastatic breast cancer patients is driven by genetic alterations such as amplifications of the CDK6 gene and loss of the retinoblastoma (RB) tumor suppressor gene.

Citations:
"	N	0	"The criterion for this task is the correctness of the information provided in the submission, compared to the reference. 

The reference states that the genetic alterations that promote CDK6 upregulation and resistance in metastatic breast cancer patients are FAT1 loss, PTEN loss, and ARID1A loss. These alterations were found in 17% of the patients analyzed in the study.

The submission, however, states that the genetic alterations driving CDK6-mediated resistance are amplifications of the CDK6 gene and loss of the retinoblastoma (RB) tumor suppressor gene. 

Comparing the two, it is clear that the submission does not match the reference. The genetic alterations mentioned in the submission are not the same as those mentioned in the reference. Therefore, the submission does not meet the criterion of correctness.

N"
What genomic alterations are enriched in metastatic breast tumors after hormonal therapy?	The Breast Cancer (MSK, Cancer Cell 2018) study found that mutations in the MAPK pathway (e.g., ERBB2 activating mutations, NF1 loss-of-function, EGFR amplifications) and alterations in key transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were significantly more common in specimens acquired after endocrine therapy. These alterations were largely mutually exclusive with ESR1 mutations and collectively affected 22% of all post-hormonal therapy tumors.	"Genomic alterations enriched in metastatic breast tumors after hormonal therapy include PIK3CA mutations, alterations in the ESR1 gene, and changes in genes associated with cell cycle regulation and signaling pathways such as ERBB2, RET, and others involved in drug resistance mechanisms.

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference provided. 

The reference mentions that the Breast Cancer study found mutations in the MAPK pathway (e.g., ERBB2 activating mutations, NF1 loss-of-function, EGFR amplifications) and alterations in key transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were significantly more common in specimens acquired after endocrine therapy. These alterations were largely mutually exclusive with ESR1 mutations and collectively affected 22% of all post-hormonal therapy tumors.

The submission, on the other hand, states that genomic alterations enriched in metastatic breast tumors after hormonal therapy include PIK3CA mutations, alterations in the ESR1 gene, and changes in genes associated with cell cycle regulation and signaling pathways such as ERBB2, RET, and others involved in drug resistance mechanisms.

Comparing the two, the submission does mention ERBB2 and ESR1, which are also mentioned in the reference. However, the submission does not mention the MAPK pathway, NF1 loss-of-function, EGFR amplifications, MYC, CTCF, FOXA1, and TBX3, which are all mentioned in the reference. Additionally, the submission introduces PIK3CA mutations and RET, which are not mentioned in the reference. 

Therefore, the submission does not convey the same primary information as the reference and introduces contradictions.

N"
How are Luminal B breast tumor subtypes determined in the TCGA dataset?	The PAM50-defined subtype predictor was used to classify breast tumors into intrinsic subtypes, including Luminal B.	"Luminal B breast tumor subtypes are determined in the TCGA dataset based on gene expression profiling, primarily using a combination of estrogen receptor status, proliferation markers, and specific gene expression signatures associated with the Luminal B subtype.

Citations:
"	N	0	"The criterion for this task is correctness, which requires the submission to convey the same primary information as the reference without introducing any contradictions.

The reference states that the PAM50-defined subtype predictor was used to classify breast tumors into intrinsic subtypes, including Luminal B. This suggests that the classification of Luminal B breast tumor subtypes in the TCGA dataset is based on the PAM50-defined subtype predictor.

The submission, on the other hand, states that Luminal B breast tumor subtypes are determined based on gene expression profiling, primarily using a combination of estrogen receptor status, proliferation markers, and specific gene expression signatures associated with the Luminal B subtype. While this may be true in a broader context, it does not specifically mention the use of the PAM50-defined subtype predictor, which is the primary information provided in the reference.

Therefore, the submission does not meet the criterion of correctness as it does not convey the same primary information as the reference and introduces a contradiction by not mentioning the PAM50-defined subtype predictor.

N"
Are there studies that include whole-genome sequencing of both tumor and matched normal samples?	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	"Yes, there are studies that include whole-genome sequencing of both tumor and matched normal samples.

Citations:
"	Y	1	"The criterion is to assess whether the submission conveys the same primary information as the reference without introducing any contradictions. 

The reference is a pan-cancer analysis of whole genomes study (ICGC/TCGA, Nature 2020). This implies that the study includes whole-genome sequencing of both tumor and matched normal samples.

The submission states that there are studies that include whole-genome sequencing of both tumor and matched normal samples. This is in line with the information provided in the reference.

Therefore, the submission meets the criterion as it conveys the same primary information as the reference without introducing any contradictions.

Y"
Are there studies containing promoter methylation data?	Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)	"Yes, there are studies containing promoter methylation data.

Citations:
"	N	0	"The criterion is to assess whether the submission conveys the same primary information as the reference without introducing any contradictions. 

The reference provided is ""Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)"". This reference seems to be a citation of a study or studies related to breast cancer, but it does not provide any explicit information about promoter methylation data.

The submission states ""Yes, there are studies containing promoter methylation data."" and provides citations. However, without the actual content of the citations, it's impossible to verify if they indeed contain promoter methylation data.

The submission does not contradict the reference, but it also does not convey the same primary information. The reference is about breast cancer studies, while the submission is about studies containing promoter methylation data. Without more context or information, it's impossible to determine if these two are related.

Therefore, based on the provided information, the submission does not meet the criterion.
N"
Are there studies with information about lipid levels in tumors?	Glioblastoma (CPTAC, Cell 2021)	"Yes, there are studies that provide information about lipid levels in tumors.

Citations:
"	N	0	"The criterion is about the correctness of the submission based on the given reference. 

The reference provided is ""Glioblastoma (CPTAC, Cell 2021)"". This seems to be a citation for a study, but it does not provide any specific information about lipid levels in tumors. 

The submission states that there are studies that provide information about lipid levels in tumors. However, without more specific information from the reference, it's impossible to determine if the submission is correct or not. 

The submission does not introduce any contradictions to the reference, but it also does not clearly align with the reference due to the lack of specific information in the reference.

Therefore, based on the given criterion, it is not possible to definitively say that the submission meets the criteria.

N"
Which studies provide information on non-coding driver mutations?	Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)	"I don't know.

Citations:
"	N	0	"The criterion is to assess if the submission conveys the same primary information as the reference without introducing any contradictions.

The reference provided is ""Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)"" which implies that this study provides information on non-coding driver mutations.

The submission, however, states ""I don't know."" This does not convey the same primary information as the reference. It also introduces a contradiction because the reference does provide a study that gives information on non-coding driver mutations, while the submission suggests that no such information is known.

Therefore, the submission does not meet the criterion.

N"
Are there studies with information about cisplatin treatment in bladder cancer?	Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)	"Yes, there are studies that provide information about cisplatin treatment in bladder cancer.

Citations:
"	N	0	"The criterion for this task is to assess whether the submission conveys the same primary information as the reference without introducing any contradictions. 

The reference provided is a citation of a study titled ""Bladder Urothelial Carcinoma (DFCI/MSK, Cancer Discov 2014)"". This suggests that the study is related to bladder cancer, but it does not provide specific information about cisplatin treatment in bladder cancer.

The submission, on the other hand, confirms that there are studies about cisplatin treatment in bladder cancer. However, it does not provide any specific citations to back up this claim.

Given this, it can be concluded that the submission does not contradict the reference, but it also does not provide the same primary information as the reference. The reference does not mention cisplatin treatment, while the submission does. 

Therefore, the submission does not meet the criterion. 

N"
Which software was used to detect short insertions and deletions in Illumina WGS bam files? A) SNVMix2, B) IGV82, C) Pindel, D) Ensembl59	C	"C) Pindel

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference answer is ""C"".

The submitted answer is ""C) Pindel"".

The submission matches the reference answer, hence it conveys the same primary information without introducing any contradictions.

Therefore, the submission meets the criterion.

Y"
Which genomic alteration is significantly associated with poor survival in patients with metastatic castration-resistant prostate cancer? A) AR, B) TP53, C) RB1, D) BRCA2	C	"B) TP53

Citations:
"	N	0	"The criterion for this task is the correctness of the submitted answer in relation to the reference answer. 

The reference answer is C) RB1, which indicates that the genomic alteration significantly associated with poor survival in patients with metastatic castration-resistant prostate cancer is RB1.

The submitted answer, however, is B) TP53. This means that the submitted answer does not match the reference answer.

Therefore, the submission does not meet the criterion of correctness as it does not convey the same primary information as the reference and introduces a contradiction.

N"
What is the median overall survival (OS) for patients treated with trastuzumab and cytotoxic chemotherapy? A) 10.5 months, B) 12.3 months, C) 13.8 months, D) 15.2 months	C	"The median overall survival (OS) for patients treated with trastuzumab and cytotoxic chemotherapy is B) 12.3 months.

Citations:
"	N	0	"The criterion for this task is correctness, which means the submitted answer should match the reference answer without introducing any contradictions. 

The reference answer is C) 13.8 months. 

However, the submitted answer is B) 12.3 months. 

Therefore, the submitted answer does not match the reference answer and introduces a contradiction. 

So, the submission does not meet the criterion.

N"
Which method was used to measure ATP content as an indicator of metabolically active cells? A) SpectraMax M2e plate reader, B) CellTiter-Glo Luminescent Cell Viability Assay, C) TaqMan Copy Number Assays, D) RPPH1 reference gene	B	"B) CellTiter-Glo Luminescent Cell Viability Assay

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference indicates the correct answer as ""B"".

The submission also indicates the answer as ""B) CellTiter-Glo Luminescent Cell Viability Assay"".

There are no contradictions introduced in the submission as it matches exactly with the reference.

Therefore, the submission meets the criterion.

Y"
What methodology was used to derive the four subtypes of CCA in the study? A) Anatomical site analysis, B) Integrative molecular clustering, C) Survival trends comparison, D) Targeted therapies evaluations	B	"B) Integrative molecular clustering

Citations:
"	Y	1	"The criterion for this task is the correctness of the submission based on the given reference. 

The reference indicates that the correct answer is ""B"". 

The submission provided by the user is also ""B) Integrative molecular clustering"". 

Therefore, the submission matches the reference exactly without introducing any contradictions. 

So, the submission meets the criterion.

Y"
Which alteration was found in 12.7% of mCRPC cases? A) CCND1 amplification, B) BRCA2 loss, C) CDK4 less common events, D) PARP inhibition	B	"B) BRCA2 loss

Citations:
"	Y	1	"The criterion for this task is correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?

The reference answer is B. The submitted answer is also B) BRCA2 loss. 

The submission matches the reference exactly, and does not introduce any contradictions. Therefore, the submission meets the criterion.

Y"
Which type of substitution was the most common in the analyzed vulvar SCC genomes? A) G>A, B) T>C, C) C>T, D) A>G	C	"C) C>T

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference answer is ""C"".

The submitted answer is ""C) C>T"".

The reference and the submitted answer both indicate the same option ""C"". However, the submitted answer provides additional information ""C>T"" which is not contradicted by the reference. 

Therefore, the submission meets the criteria as it conveys the same primary information as the reference without introducing any contradictions. 

Y"
What genetic alteration was frequently detected in recurrent gliomas characterized by presence of an IDH mutation but without 1p/19q codeletion? A) Gene amplification, B) Chromosomal translocation, C) Acquired aneuploidy, D) Point mutation	C	"A) Gene amplification

Citations:
"	N	0	"The criterion is the correctness of the submission based on the reference provided. 

The reference indicates that the correct answer to the question is ""C) Acquired aneuploidy"". 

However, the submission provided the answer as ""A) Gene amplification"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction. 

So, the submission does not meet the criterion. 

N"
Which tool was used in Washington University's analytic strategy to union Samtools and SomaticSniper calls? A) Bam-readcount, B) Joinx, C) Strelka, D) VarScan	B	"B) Joinx

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference answer is ""B"", which corresponds to ""Joinx"" in the multiple-choice question.

The submitted answer is ""B) Joinx"", which is the same as the reference answer.

Therefore, the submission meets the criterion as it conveys the same primary information as the reference without introducing any contradictions.

Y"
Which sequencing platform was used for enriched exome libraries in the study? A) Genome Analyzer II, B) NovaSeq 6000, C) HiSeq 2000, D) MiniSeq	C	"C) HiSeq 2000

Citations:
"	Y	1	"The criterion is correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?

The reference answer is ""C"". The submitted answer is ""C) HiSeq 2000"". 

The reference answer and the submitted answer are the same, indicating that the sequencing platform used for enriched exome libraries in the study was ""C) HiSeq 2000"". 

Therefore, the submission does not introduce any contradictions and conveys the same primary information as the reference. 

So, the submission meets the criterion.

Y"
Which genes were not included in earlier versions of the MSK-IMPACT panel? A) PPM1D, B) SRSF2, C) SRCAP, D) ZNF318	A	"PPM1D and SRSF2 were not included in earlier versions of the MSK-IMPACT panel.

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference. The reference indicates that the correct answer is ""A"", which corresponds to the gene ""PPM1D"". 

In the submission, the user has mentioned that ""PPM1D and SRSF2 were not included in earlier versions of the MSK-IMPACT panel."" This means that the user has correctly identified ""PPM1D"" as a gene that was not included in earlier versions of the panel, which aligns with the reference. 

However, the user has also mentioned ""SRSF2"", which is not indicated in the reference. This introduces a contradiction, as the reference only mentions ""PPM1D"". 

Therefore, the submission does not meet the criterion of conveying the same primary information without introducing any contradictions. 

N"
Which method was used for ribosomal RNA (rRNA) filtering in the transcriptome analysis? A) TrimGalore, B) SortMeRNA, C) Tuxedo Suite, D) FusionMap	B	"B) SortMeRNA

Citations:
"	Y	1	"The criterion is the correctness of the submission based on the reference. 

The reference indicates that the correct answer is ""B"". 

The submission also indicates ""B) SortMeRNA"" as the answer. 

Therefore, the submission matches the reference and does not introduce any contradictions. 

So, the submission meets the criterion. 

Y"
Which genes showed stronger inhibition upon double KD of YAP and TAZ compared to individual KD? A) TEAD, B) CTGF, C) FOSL1, D) YAP	B	"B) CTGF

Citations:
"	Y	1	"The criterion for this task is correctness, which means the submitted answer should match the reference without introducing any contradictions.

The reference answer is B.

The submitted answer is B) CTGF.

The submitted answer matches the reference answer exactly, and no contradictions are introduced.

Therefore, the submission meets the criterion.

Y"
Which mutation in SPOP was identified in the document? A) E78X, B) E78K, C) E74K, D) E80K	B	"A) E78X

Citations:
"	N	0	"The criterion is the correctness of the information provided in the submission, compared to the reference. 

The reference indicates that the correct answer to the question ""Which mutation in SPOP was identified in the document?"" is B) E78K.

The submission, however, states that the correct answer is A) E78X.

Therefore, the submission does not meet the criterion of correctness, as it does not convey the same primary information as the reference and introduces a contradiction.

N"
Which fusion partner is involved with EWSR1 rearrangements in Patient 2? A) POU5F1, B) KLF15, C) PBX1, D) ZNF444	B	"The fusion partner involved with EWSR1 rearrangements in Patient 2 is A) POU5F1.

Citations:
"	N	0	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference indicates that the correct answer to the input question is ""B) KLF15"". 

However, the submission states that the correct answer is ""A) POU5F1"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction. 

N"
Which gene undergoes focal deletions in astrocytic origin tumors with therapy-induced hypermutation? A) CTGF, B) CDKN2A/B, C) RB1, D) MMR	B	"B) CDKN2A/B

Citations:
"	Y	1	"The criterion for this task is the correctness of the submission. The submission should convey the same primary information as the reference without introducing any contradictions.

The reference answer is ""B"". The submitted answer is ""B) CDKN2A/B"". 

The submission matches the reference answer, as both indicate the same option ""B"". The submission also provides the full name of the gene associated with option ""B"", which does not introduce any contradictions but rather provides additional clarity.

Therefore, the submission meets the criteria.

Y"
Which mutation conferred resistance to RAF and MEK inhibition? A) BRAF mutation, B) MEK1 mutations, C) ERK mutation, D) MITF amplification	B	"B) MEK1 mutations

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference answer is ""B"".

The submitted answer is ""B) MEK1 mutations"".

The submitted answer matches the reference answer, and does not introduce any contradictions. Therefore, the submission meets the criterion.

Y"
Which algorithm was used to identify tumors with shared genetic features? A) Fisher test, B) Benjamini-Hochberg method, C) Non-negative matrix factorization consensus clustering, D) GENE-E	C	"C) Non-negative matrix factorization consensus clustering

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference indicates that the correct answer is ""C"". 

The submission also indicates that the correct answer is ""C) Non-negative matrix factorization consensus clustering"".

Therefore, the submission conveys the same primary information as the reference without introducing any contradictions.

Y"
Which characteristic is predominant in lower esophageal and junctional adenocarcinomas according to the TCGA study? A) Microsatellite instability (MSI), B) Chromosomal instability (CIN), C) Genomically stable (GS), D) High mutation burden	B	"B) Chromosomal instability (CIN)

Citations:
"	Y	1	"The criterion for this task is the correctness of the submission based on the given reference. 

The reference indicates that the correct answer is ""B"". 

The submission also indicates that the correct answer is ""B) Chromosomal instability (CIN)"". 

Therefore, the submission matches the reference without introducing any contradictions. 

So, the submission meets the criterion. 

Y"
What type of cancer is primarily discussed in the document? A) Non-small cell lung cancer, B) Melanomas, C) High grade serous ovarian cancer, D) Breast cancer	C	"I don't know.

Citations:
"	N	0	"The criterion is assessing the correctness of the submission based on the reference. The reference indicates that the correct answer is ""C) High grade serous ovarian cancer"". 

The submission, however, does not provide any answer to the question, instead stating ""I don't know."" This does not convey the same primary information as the reference, and therefore does not meet the criterion.

N"
Which type of tumors are indicated to be dependent on bromodomain proteins for maintaining MYB driven enhancer programs? A) Grade 1 tumors, B) Grade 2 tumors, C) Grade 3 tumors, D) Grade 4 tumors	B	"C) Grade 3 tumors

Citations:
"	N	0	"The criterion is the correctness of the submission based on the reference provided. 

The reference indicates that the correct answer to the question is ""B) Grade 2 tumors"". 

However, the submission provided the answer as ""C) Grade 3 tumors"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction. 

So, the submission does not meet the criterion. 

N"
Which institution approved the standards of care for the experiments conducted in the study? A) NIH, B) MD Anderson Cancer Center, C) Harvard University, D) Mayo Clinic	B	"B) MD Anderson Cancer Center

Citations:
"	Y	1	"The criterion is to assess the correctness of the submission based on the reference. The reference indicates that the correct answer is ""B"". 

The submission provided is ""B) MD Anderson Cancer Center"". This matches with the reference answer, which is ""B"". 

Therefore, the submission does not introduce any contradictions and conveys the same primary information as the reference. 

So, the submission meets the criterion.

Y"
Which mutation frequency was consistent with heterozygous mutations present in every leukemic cell at diagnosis in INF002? A) 0.426, B) 0.236, C) 0.114, D) 0.058	A	"A) 0.426

Citations:
"	Y	1	"The criterion for this task is correctness. The submission should convey the same primary information as the reference without introducing any contradictions.

The reference answer is ""A"". The submitted answer is also ""A"". Therefore, the submission conveys the same primary information as the reference.

The submission does not introduce any contradictions as it matches the reference answer exactly.

Therefore, the submission meets the criterion.

Y"
Which instrument was used for DNA shearing in whole-genome sequencing? A) Picogreen, B) Covaris E210, C) Qiagen Min-Elute, D) Pippin Prep system	B	"B) Covaris E210

Citations:
"	Y	1	"The criterion is to assess the correctness of the submission based on the reference. 

The reference indicates that the correct answer to the question is ""B"". 

The submission also indicates ""B) Covaris E210"" as the answer to the question. 

Therefore, the submission conveys the same primary information as the reference without introducing any contradictions. 

So, the submission meets the criterion. 

Y"
What was the median mutation rate in CSF ctDNA observed in the study? A) 0.7-0.8 mutations/Mb, B) 2.2 mutations/Mb, C) 4.46 mutations/Mb, D) 4.90 mutations/Mb	D	"C) 4.46 mutations/Mb

Citations:
"	N	0	"The criterion for this task is correctness, which means the submitted answer should match the reference answer without introducing any contradictions.

The reference answer is D) 4.90 mutations/Mb.

The submitted answer is C) 4.46 mutations/Mb.

Comparing the two, it is clear that the submitted answer does not match the reference answer. Therefore, the submission does not meet the criterion of correctness.

N"
Which mutations were found to coexist in separate metastatic lesions from a single patient? A) FOXA1 and MAPK, B) ERBB2 and ESR1, C) YAP and TAZ, D) CTGF and CYR61	B	"B) ERBB2 and ESR1

Citations:
"	Y	1	"The criterion is the correctness of the submission based on the reference. 

The reference indicates that the correct answer is ""B"". 

The submission also indicates that the correct answer is ""B) ERBB2 and ESR1"". 

Therefore, the submission conveys the same primary information as the reference without introducing any contradictions. 

So, the submission meets the criterion. 

Y"
Which chemotherapy agent was linked to a higher likelihood of CH-PD with increased exposure? A) Carboplatin, B) Methotrexate, C) Cyclophosphamide, D) Paclitaxel	A	"C) Cyclophosphamide

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference provided. 

The reference indicates that the correct answer to the question is ""A) Carboplatin"". 

However, the submission provided the answer as ""C) Cyclophosphamide"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction. 

N"
Which therapy was unique to patient RC-MSK-003? A) FOLFOX, B) Capecitabine + Oxaliplatin + Bevacizumab, C) FOLFIRI, D) Cetuximab	B	"B) Capecitabine + Oxaliplatin + Bevacizumab

Citations:
"	Y	1	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference indicates that the correct answer is ""B"". 

The submission also indicates that the correct answer is ""B) Capecitabine + Oxaliplatin + Bevacizumab"". 

Therefore, the submission conveys the same primary information as the reference without introducing any contradictions. 

Y"
Which gene co-localized with the copy gain in the kataegis region? A) TP53, B) DHX38, C) APC, D) FBXW7	B	"B) DHX38

Citations:
"	Y	1	"The criterion for this task is the correctness of the submission based on the given reference. 

The reference indicates that the correct answer to the question is ""B"". 

The submission provided by the user is ""B) DHX38"", which matches the reference answer. 

Therefore, the submission meets the criterion of correctness as it conveys the same primary information as the reference without introducing any contradictions. 

Y"
Which genetic alteration is a hallmark of low hypodiploid ALL? A) IKZF3, B) TP53, C) NRAS, D) FLT3	B	"A) IKZF3

Citations:
"	N	0	"The criterion is to assess the correctness of the submission based on the reference. 

The reference indicates that the correct answer to the question ""Which genetic alteration is a hallmark of low hypodiploid ALL?"" is ""B) TP53"". 

However, the submission provided the answer as ""A) IKZF3"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction. 

So, the submission does not meet the criterion. 

N"
Which method was used for microsatellite instability testing in tumor samples? A) CTGF assay, B) Wnt pathway analysis, C) MSI detection kit, D) Rspo2 transposon analysis	C	"C) MSI detection kit

Citations:
"	Y	1	"The criterion is to assess the correctness of the submission based on the reference. 

The reference answer is ""C"". 

The submitted answer is ""C) MSI detection kit"". 

The submission matches the reference exactly, and does not introduce any contradictions. 

Therefore, the submission meets the criterion. 

Y"
Which gene's expression was significantly lower in tumors with mutations at the chromosome 6 hotspot? A) SPG20, B) CTCF, C) KCNQ5, D) EGFR	C	"B) CTCF

Citations:
"	N	0	"The criterion is ""correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?""

The reference indicates that the correct answer to the question is ""C) KCNQ5"". However, the submission provided the answer as ""B) CTCF"". 

Therefore, the submission does not convey the same primary information as the reference and introduces a contradiction by providing a different answer. 

N"
Which cell line was used for knockdown and XTT proliferation assays in the study? A) HeLa, B) H1299, C) 293T, D) SCCOHT	C	"B) H1299

Citations:
"	N	0	"The criterion for this task is correctness, which means the submitted answer should match the reference without introducing any contradictions.

The reference answer is ""C"", which corresponds to the cell line ""293T"".

The submitted answer is ""B) H1299"", which is different from the reference answer.

Therefore, the submitted answer does not meet the criterion of correctness.

N"
What was the primary focus of the TCGA PanCanAtlas initiative as mentioned in the document? A) DNA repair alterations, B) Metabolic pathway alterations, C) Mitogenic signaling pathways, D) Splicing mutations	C	"The primary focus of the TCGA PanCanAtlas initiative was A) DNA repair alterations.

Citations:
"	N	0	"The criterion for this task is correctness. This means that the submitted answer should match the reference answer without introducing any contradictions.

The reference answer is C) Mitogenic signaling pathways.

The submitted answer is A) DNA repair alterations.

Comparing the two, it is clear that the submitted answer does not match the reference answer. Therefore, the submission does not meet the criterion of correctness.

N"
What is the prevalence range of the MYB-NFIB fusion gene in salivary gland AdCCs according to the document? A) 23% to 100%, B) 28% to 100%, C) 50% to 80%, D) 10% to 50%	B	"B) 28% to 100%

Citations:
"	Y	1	"The criterion for this task is correctness. The submission should convey the same primary information as the reference without introducing any contradictions.

The reference provided is B. The submission also selected B) 28% to 100% as the answer. 

Therefore, the submission matches the reference exactly and does not introduce any contradictions. 

So, the submission meets the criterion.

Y"
Which gene is highly expressed in lung alveolar epithelium and its knockdown leads to increased propensity for lung adenocarcinoma development? A) ANK1, B) CLDN18, C) PTPRCAP, D) LCK	B	"B) CLDN18

Citations:
"	Y	1	"The criterion is to assess the correctness of the submission based on the reference. 

The reference answer is B. 

The submitted answer is B) CLDN18. 

The submission matches the reference without introducing any contradictions. 

Therefore, the submission meets the criterion. 

Y"
Which type of genomic alteration was found in one HNSCC patient that indicated sensitivity to cisplatin? A) Missense mutation, B) Splicing mutation, C) Germline heterozygous deletion, D) Intronic mutation	C	"C) Germline heterozygous deletion

Citations:
"	Y	1	"The criterion for this task is correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?

The reference answer is C, which corresponds to ""Germline heterozygous deletion"". 

The submitted answer is also C, ""Germline heterozygous deletion"". 

Therefore, the submission does convey the same primary information as the reference without introducing any contradictions. 

So, the submission meets the criterion.

Y"
Which method was used to quantify the pathologic response in the primary tumor bed? A) NRF2 pathway evaluation, B) NPA calculation, C) Percentage treatment effect, D) Myc pathway analysis	C	"B) NPA calculation

Citations:
"	N	0	"The criterion is the correctness of the submission based on the reference. The reference indicates that the correct answer to the question is ""C) Percentage treatment effect"". However, the submission provided the answer as ""B) NPA calculation"". This means that the submission does not convey the same primary information as the reference and introduces a contradiction. Therefore, the submission does not meet the criterion.

N"
Which biomarker is associated with a response to immune-checkpoint inhibitors? A) Tumor mutation burden, B) MSI-H, C) MMR mutational signature, D) cfDNA sequencing assay	B	"B) MSI-H

Citations:
"	Y	1	"The criterion for this task is correctness: Given the reference, does the submission convey the same primary information without introducing any contradictions?

The reference answer is B. The submitted answer is also B) MSI-H. 

The submission matches the reference exactly, and does not introduce any contradictions. 

Therefore, the submission meets the criterion.

Y"
